Cheng CS, Rai K, Garber M, et al. Semiconductor-based DNA sequencing of histone modification states. Nat Commun. 2013;4:2672. doi:10.1038/ncomms3672
Ott PA, Fritsch EF, Wu CJ, Dranoff G. Vaccines and melanoma. Hematol Oncol Clin North Am. 2014;28(3):559-69. doi:10.1016/j.hoc.2014.02.008
Gupta S, Artomov M, Goggins W, Daly M, Tsao H. Gender Disparity and Mutation Burden in Metastatic Melanoma. J Natl Cancer Inst. 2015;107(11). doi:10.1093/jnci/djv221
Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350(6257):207-11. doi:10.1126/science.aad0095
Nagaraja AK, Bass AJ. Hitting the Target in BRAF-Mutant Colorectal Cancer. J Clin Oncol. 2015;33(34):3990-2. doi:10.1200/JCO.2015.63.7793
Neel VA, Todorova K, Wang J, et al. Sustained Akt Activity Is Required to Maintain Cell Viability in Seborrheic Keratosis, a Benign Epithelial Tumor. J Invest Dermatol. 2016;136(3):696-705. doi:10.1016/j.jid.2015.12.023
Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7:10391. doi:10.1038/ncomms10391
McGranahan N, Furness AJS, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463-9. doi:10.1126/science.aaf1490
Tirosh I, Izar B, Prakadan SM, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352(6282):189-96. doi:10.1126/science.aad0501
Chen G, McQuade JL, Panka DJ, et al. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol. 2016;2(8):1056-64. doi:10.1001/jamaoncol.2016.0509